The effects of Δ9‐tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide
- 1 June 2005
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 145 (4) , 514-526
- https://doi.org/10.1038/sj.bjp.0706218
Abstract
1 Delta9-tetrahydrocannabinol (THC) produces varying effects in mesenteric arteries: vasorelaxation (third-order branches, G3), modest vasorelaxation (G2), no effect (G1) and vasoconstriction (the superior mesenteric artery, G0). 2 In G3, vasorelaxation to THC was inhibited by pertussis toxin, but was unaffected by the CB1 receptor antagonist, AM251 (1 microM), incubation with the TRPV1 receptor agonist capsaicin (10 microM, 1 h), the TRPV1 receptor antagonist capsazepine (10 microM) or de-endothelialisation. 3 In G3, vasorelaxation to THC was inhibited by high K+ buffer, and by the following K+ channel inhibitors: charybdotoxin (100 nM), apamin (500 nM) and barium chloride (30 microM), but not by 4-aminopyridine, glibenclamide or tertiapin. 4 In G3, THC (10 and 100 microM) inhibited the contractile response to Ca2+ in a Ca2+-free, high potassium buffer, indicating that THC blocks Ca2+ influx. 5 In G0, the vasoconstrictor responses to THC were inhibited by de-endothelialisation and SR141716A (100 nM), but not by the endothelin (ET(A)) receptor antagonist FR139317 (1 microM).THC (1 and 10 microM) antagonised vasorelaxation to anandamide in G3 but not G0. THC did not antagonise the noncannabinoid verapamil, capsaicin or the CB1 receptor agonist CP55,940. 6 THC (10 and 100 microM) inhibited endothelium-derived relaxing factor (EDHF)-mediated responses to carbachol in a manner similar to the gap junction inhibitor 18alpha-glycyrrhetinic acid. 7 These data show that THC causes vasorelaxation through activation of K+ channels and inhibition of Ca2+ channels, and this involves non-CB1, non-TRPV1 but G-protein-coupled receptors. In G0, THC does not cause relaxation and at high concentrations causes contractions. Importantly, THC antagonises the effects of anandamide, possibly through inhibition of EDHF activity.Keywords
This publication has 42 references indexed in Scilit:
- Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteriesBritish Journal of Pharmacology, 2004
- Δ9-Tetrahydrocannabinol antagonizes endocannabinoid modulation of synaptic transmission between hippocampal neurons in cultureNeuropharmacology, 2004
- Characterisation of the vasorelaxant properties of the novel endocannabinoid N‐arachidonoyl‐dopamine (NADA)British Journal of Pharmacology, 2004
- Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1Nature, 2004
- The extracellular regulated kinases (ERK) 1/2 mediate cannabinoid‐induced inhibition of gap junctional communication in endothelial cellsBritish Journal of Pharmacology, 2002
- Characterization using FLIPR of rat vanilloid receptor (rVR1) pharmacologyBritish Journal of Pharmacology, 2000
- Cannabinoid CB1 receptors fail to cause relaxation, but couple via Gi/Go to the inhibition of adenylyl cyclase in carotid artery smooth muscleBritish Journal of Pharmacology, 1999
- Mesenteric Vasodilation Mediated by Endothelial Anandamide ReceptorsHypertension, 1999
- The actions of some cannabinoid receptor ligands in the rat isolated mesenteric arteryBritish Journal of Pharmacology, 1998
- Complex pharmacology of natural cannabivoids: Evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptorsLife Sciences, 1998